Silo Pharma (SILO) Operating Income (2018 - 2026)
Silo Pharma (SILO) posted Operating Income of -$1.6 million for Q1 2026, down 102.75% sequentially from -$786524.0 in Q4 2025, and down 45.75% YoY from -$2.9 million in Q1 2025.
Silo Pharma (SILO) Operating Income (2018 - 2026) Analysis & Trends
Silo Pharma has reported Operating Income for 9 years, with the latest figure at -$1.6 million in Q1 2026.
- Quarterly Operating Income fell 45.75% year-over-year to -$1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.8 million (up 2.83% YoY) and the FY2025 annual result came in at -$4.3 million, up 9.03% from the prior year.
- Operating Income retreated to -$1.6 million in Q1 2026 per SILO's latest filing, from -$786524.0 in the prior quarter.
- Over five years, Operating Income peaked at -$494285.0 in Q2 2022 and troughed at -$1.8 million in Q4 2024.
- A 5-year average of -$1.1 million and a median of -$1.0 million in 2024 frame the typical range for Operating Income.
- The sharpest annual moves came in 2023 and 2025: Operating Income slumped 125.58% in 2023, then soared 56.63% in 2025.
- Over 5 years, Operating Income stood at -$1.7 million in 2022, then advanced by 29.77% to -$1.2 million in 2023, then tumbled by 55.82% to -$1.8 million in 2024, then jumped by 56.63% to -$786524.0 in 2025, then plunged by 102.75% to -$1.6 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$1.6 million, -$786524.0, and -$1.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Silo Pharma | 3.04 Mn | 3.04 Mn | - | -928,949.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -928,949.00 |
| Mar 31, 2026 | -1.59 Mn |
| Dec 31, 2025 | -786,524.00 |
| Sep 30, 2025 | -1.15 Mn |
| Jun 30, 2025 | -1.25 Mn |
| Mar 31, 2025 | -1.09 Mn |
| Dec 31, 2024 | -1.81 Mn |
| Sep 30, 2024 | -1.01 Mn |
| Jun 30, 2024 | -1.00 Mn |
| Mar 31, 2024 | -879,513.00 |
| Dec 31, 2023 | -1.16 Mn |
| Sep 30, 2023 | -773,398.00 |
| Jun 30, 2023 | -1.11 Mn |
| Mar 31, 2023 | -803,485.00 |
| Dec 31, 2022 | -1.66 Mn |
| Sep 30, 2022 | -949,154.00 |
| Jun 30, 2022 | -494,285.00 |
| Mar 31, 2022 | -527,259.00 |
| Dec 31, 2021 | -942,416.00 |
| Sep 30, 2021 | -463,942.00 |